May 13, 2016

New research better defines which patients will respond to colorectal cancer drug

The University Health Network announced today that Dr. Geoffrey Liu, clinician-scientist at Princess Margaret Cancer Centre, and his team have identified a blood marker that better defines which patients will respond to the drug cetuximab. The research applies to patients with metastatic colorectal cancer.

See Dr. Liu explain his findings:

Dr. Liu’s research was funded by the Ontario Institute of Cancer Research, the Alan B. Brown Chair in Molecular Genomics, the Cancer Care Ontario Chair in Experimental Therapeutics and Population Studies, the Canadian Cancer Society, and The Princess Margaret Cancer Foundation. The research was published today in the journal Clinical Cancer Research.

See full release here:
Researchers Discover Blood Marker That Better Defines Who Will Respond To Drug Used In Metastatic Colorectal Cancer